PRESS RELEASE published on 07/15/2024 at 09:30, 1 year 11 months ago Andera Partners’ portfolio company Amolyt Pharma completes acquisition by AstraZeneca Andera Partners' portfolio company Amolyt Pharma has been acquired by AstraZeneca for $1.05 billion, enhancing AstraZeneca's Rare Disease late-stage pipeline and bone metabolism franchise Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Andera Partners
BRIEF published on 07/09/2024 at 08:15, 1 year 11 months ago Andera Partners codirige la série A de 63 millions d'euros pour la biotechnologie SciRhom Produits Biopharmaceutiques Maladies Auto-immunes Financement De Série A Partenaires Andera SciRhom
BRIEF published on 07/09/2024 at 08:15, 1 year 11 months ago Andera Partners Co-Leads €63 Million Series A for Biotech SciRhom Series A Financing Biopharmaceuticals Andera Partners Autoimmune Disorders SciRhom
PRESS RELEASE published on 07/09/2024 at 08:10, 1 year 11 months ago Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom to advance novel iRhom2 antibody therapy towards clinical proof-of-concept Andera Partners SciRhom Autoimmune Biotech Series A Round IRhom2 Antibody
BRIEF published on 03/14/2024 at 11:15, 2 years 3 months ago Tubulis, la société de portefeuille d'Andera Partners, obtient un financement de série B2 de 128 millions d'euros Essais Cliniques Tubulis Partenaires Andera Financement De Série B2 Développement ADC
BRIEF published on 03/14/2024 at 11:15, 2 years 3 months ago Andera Partners’ Portfolio Company Tubulis Secures €128 Million in Series B2 Financing Clinical Trials Andera Partners Tubulis Series B2 Financing ADC Development
PRESS RELEASE published on 03/14/2024 at 11:10, 2 years 3 months ago Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 financing to accelerate ADC pipeline development Andera Partners Tubulis €128 Million Series B2 ADC Pipeline Biotech Financing
BRIEF published on 03/14/2024 at 09:05, 2 years 3 months ago AstraZeneca acquiert Amolyt Pharma pour un montant pouvant atteindre 1,05 milliard de dollars Acquisition Biopharmaceutique AstraZeneca Amolyt Pharma Maladies Rares
BRIEF published on 03/14/2024 at 09:05, 2 years 3 months ago AstraZeneca Acquires Amolyt Pharma for up to $1.05 Billion Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Rare Diseases
PRESS RELEASE published on 03/14/2024 at 09:00, 2 years 3 months ago Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca Amolyt Pharma, a clinical-stage biopharmaceutical company specializing in therapeutic peptides, is being acquired by AstraZeneca for $1.05 billion. The transaction is expected to close in Q3 2024 Acquisition AstraZeneca Amolyt Pharma Therapeutic Peptides Rare Endocrine Diseases
Published on 07/03/2026 at 23:00, 1 day 4 hours ago Eagle Plains Partner Refined Energy Announces Final Results for Winter 2026 Drill Program at Dufferin West
Published on 07/03/2026 at 21:28, 1 day 6 hours ago Trifecta Gold Announces Closing of $1.66 Million Private Placement
Published on 07/03/2026 at 19:30, 1 day 8 hours ago Polaris Renewable Energy Announces Q2 2026 Investor Call Details
Published on 07/03/2026 at 13:30, 1 day 14 hours ago Nextech3D.ai Unveils Strategic AI Growth Roadmap Focused on Workforce Intelligence and Event Technology Innovation
Published on 07/04/2026 at 17:35, 9 hours 57 minutes ago Vantage Introduces 24/7 Gold CFD Trading with XAUUSD247
Published on 07/04/2026 at 11:01, 16 hours 31 minutes ago EQS-Adhoc: Continental AG: Continental AG Sells ContiTech Group Sector
Published on 07/04/2026 at 09:05, 18 hours 27 minutes ago Velo x McLaren Mastercard Formula 1® Team Relaunches Live Your Fandom to Bring Fans Closer to the Sport They Love
Published on 07/03/2026 at 19:00, 1 day 8 hours ago PATRIMOINE ET COMMERCE: BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE AU 30 JUIN 2026
Published on 07/03/2026 at 18:55, 1 day 8 hours ago Saudia Arabia's Mabani Aljazeera Group invests in Tatu City's Jabali Towers development
Published on 07/03/2026 at 21:49, 1 day 5 hours ago Safran annonce la fin des négociations concernant le projet d'acquisition d’Exail Technologies.
Published on 07/03/2026 at 21:49, 1 day 5 hours ago Safran announces the end of negotiations regarding the contemplated acquisition of Exail Technologies.
Published on 07/03/2026 at 18:42, 1 day 8 hours ago Total number of voting rights and shares making up the share capital at June 30, 2026
Published on 07/03/2026 at 18:36, 1 day 8 hours ago Disclosure of transactions in own shares from July 1 to July 3, 2026
